genomic & iMmune characterization
Unlocking Molecular Insights for Blood Cancer Care
Predicta is building a molecular insights platform for blood cancer care. From a single blood sample, we generate longitudinal genomic and immune insights that help clinicians and researchers better understand disease biology, guide treatment decisions, and monitor disease evolution over time.
Our Commitment Starts with an Integrated View of the Genome & Immune System
Predicta delivers a complete picture of a patient’s disease from a routine blood draw or bone marrow sample. Using whole-genome sequencing of circulating tumor cells, it uncovers genetic changes that standard tests miss – giving physicians deeper insight to guide therapy selection and track how the disease is evolving over time.
GenoPredicta
Genomic Characterization
Provides full genomic insights of rare circulating tumor cells, including Measurable Residual Disease (“MRD”) – by capturing the structural variants, copy number changes, and clonal evolution that guide therapy selection across the full journey of a patient’s disease.
ImmunoPredicta
Single-Cell Immune Profiling
Adds single cell immune cell profiling, including T-Cell Receptors (“TCR”), from the same sample – revealing how a patient’s immune system is engaging their disease, a dimension of biology that no other diagnostic approach currently offers.
*ImmunoPredicta Available Late 2026.
The Predicta Advantage
Blood-Based Testing
Generate comprehensive molecular insights from a routine blood draw, reducing reliance on invasive bone marrow biopsies while enabling repeat assessment over time.
Comprehensive Molecular Insights
Whole-genome profiling captures genomic alterations that targeted panels and FISH testing often miss, providing a deeper view of disease biology and evolution.
Integrated Immune Profiling
Characterize immune-cell composition and dynamics alongside genomic alterations to better understand treatment response and disease progression.
Longitudinal Disease Monitoring
Track molecular changes over time to assess treatment response, monitor progression, and support MRD assessment throughout the patient journey.
Rare Cell & MRD Detection
Analyze circulating tumor cells and rare-cell populations with high sensitivity, enabling detection of clinically meaningful signals often missed by conventional approaches.
Biopharma & Clinical Development
Support biomarker discovery, patient stratification, companion diagnostic development, and clinical trial acceleration through integrated molecular insights.
Advantages of WGS-Based Profiling From Sorted Tumor Cells
| FISH | NGS Panels | GenoPredicta (WGS) | ||
|---|---|---|---|---|
| Sample Type | Marrow Only* | Marrow Only* | Marrow | Blood (CTCs) |
| Minimally Invasive | close | close | close | check |
| Cell Requirements | 50-200/probe | Generally > 1,600 (10ng DNA) | ~50 | ~50 |
| Genetic Alterations | check | check | ||
| SVs (Translocations) | Only Canonical (IGH) | Only Canonical/Covered | ||
| CNVs | Limited | Limited | ||
| Focal CNVs | close | Only if Covered | ||
| SNVs/Indels | close | Only if Covered | ||
| Copy-Neutral LOH | close | Limited | ||
| Satisfies IMS-IMWG/NCCN guidelines | close | check | check | check |
| Detects mutations / deletions of therapeutic targets | close | Only if covered | check | check |
| Discovers new resistance markers | close | Only if covered | check | check |
| Robust detection of subclonal alterations | close | Limited to genes in panel | check | check |
| Can capture all lesions/ clones, not just sampled site | close | close | close | check |
*Assuming high % of tumor cells in sample (e.g., CD138-selected cells)
Molecular Insights Across the Care Journey
For Providers
Clinical and Diagnostic Decision Support
Access integrated genomic and immune insights to support therapy selection, risk stratification, MRD assessment, and longitudinal monitoring.
Latest Updates
Predicta Biosciences and CIMA LAB Diagnostics Announce Agreement to Advance Ultrasensitive Blood-Based Diagnostics for Multiple Myeloma and Other Hematological Malignancies
Predicta Biosciences Appoints Dr. Craig L. Tendler as Independent Director to its Board
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
Predicta Newsletter
Enter your email address to subscribe.
Enter Email Address:
Predicta Biosciences
750 Main Street, Lab 413
Cambridge, MA 02139